Educational Activities Archives

This module reviews features of skin and soft tissue infections among people who inject drugs, reviews risk factors for Hepatitis C (HCV) and HIV, describes prevention interventions for HCV and HIV, and discusses treatment approaches for HCV and HIV in patients with opioid use disorder.

Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.

In this webinar, researchers from the Social Action Lab at the University of Pennsylvania will discuss a novel, virtual social-behavioral intervention, GROV (Grid for Reduction of Regional Vulnerability), which is funded by the National Institute on Drug Abuse (NIDA) under the DP01 mechanism led by PI Dolores Albarracin. The presentation will showcase how the intervention seeks to foster effective social regulation of community challenges as a way of promoting HIV and HCV testing, preventing overdoses, seeking mental and physical health treatments, establishing social relationships, etc. The research team will delve into the intervention’s design and procedures and share preliminary results during the webinar, followed by a question-and-answer session for attendees.

As the opioid use crisis continues to progress, communities across the country are now being faced with additional dangers such as the misuse of Xylazine, a powerful sedative commonly used for animals in the drug supply. Recent studies indicate these potent substances when used with opioids increase overdose risk and complicates treatment and long-term healthcare. Join us today as we discuss the history and context of Xylazine and opioid use as well as options for treatment and care.

How should I monitor liver function tests in patients who are receiving naltrexone or extended-release naltrexone for their treatment of opioid and or alcohol use disorders? What should I do if a patient receiving naltrexone does develop evidence of a severe elevation of liver function tests or acute hepatitis?